12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA
Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11
World Orphan Drug Congress, being held May 23-25 in Washington, D.C.
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences:
Event: 12th Drug Discovery Strategic Summit 2023
Date: May 3-4 2023
Location: Boston, MA
Registration: Link
Event: Sidoti Micro-Cap Virtual Conference
Date: May 10-11, 2023
Registration: Link
Webcast: Link
Event: World Orphan Drug Congress
Date: May 23-25, 2023
Location: Gaylord National Resort and Convention Center in Washington, D.C.
Registration: Link
“We look forward to attending May’s prestigious events and proudly showcasing our lead drug candidate, HSB-1216, to scientists, investors, and clinicians from the global scientific and financial community,” said Randy Milby, Hillstream BioPharma’s Founder and CEO. “Our novel ferroptosis mechanism combined with our next generation QuatramerTM tumor targeting platform offers tremendous potential for treating drug-resistant devastating cancers, and we look forward to communicating our innovative scientific research and therapeutic drug development as well as the value proposition of our business.
“We continue to advance HSB-1216 and HSB-3215 through pre-clinical studies in our lab. Having recently engaged OncoBay Clinical as a clinical research organization (CRO), we are readying HSB-1216 for its planned IND filing with the FDA later this year,” he added.
To schedule a meeting with the management team at any of the following events, please email investorrelations@hillstreambio.com.
About Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company anticipates submitting an investigational new drug application and plans to initiate a clinical study in the second half of 2023 with HSB-1216, which targets ferroptosis -- an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) of drug resistant cancers. The Company’s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique epitopes with a novel mechanism of action. The erbB/HER family of cell surface proteins include well-known and validated drug targets including HER2 and HER3 found in multiple solid tumors, including breast, lung, GYN, endocrinological and CNS. For more information, please visit: www.hillstreambio.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Hillstream’s expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2022 and our periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Hillstream does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Investor Relations Contact
Email: investorrelations@hillstreambio.com
